Novartis BP meds get FDA nod; Sweden's Meda to buy chunk of Valeant;

> Schering-Plough's stock fell on the surprising news that the FDA rejected Bridion (sugammadex), a treatment to reverse muscle relaxation during general anesthesia. Report

> The FDA gave its blessing to two single-pill combination drugs for treating high blood pressure, Diovan HCT and Exforge, from Novartis, the drugmaker said Monday. Release | Report

> Swedish pharmaceutical firm Meda said it would buy a large chunk of the European operations of American Valeant for $392 million, boosting its presence in Britain and giving it an entry into Russia. Release

> Mexico rolled back a rule that had required AIDS drug companies to maintain manufacturing plants in that country to sell any generic drugs there. Report

> Czech-based generics drug maker Zentiva reported a 19 percent rise in first-half net profit, as foreign units began to contribute to the group's profits. Report

> Caraco Laboratories launched its generic version of Abbott Laboratories' Depakote, a seizure and bipolar disorder treatment. Report

> India's Orchid Chemicals & Pharmaceuticals announced that it received European Union approval for Piperacillin and Tazobactam for injection. Report

> Versant Ventures has pulled together $500 million to fund life science companies. The investment group says it will target approximately 30-35 medical device, biotech, and pharmaceutical investments in the U.S. with a focus on funding early-stage and seed opportunities. Report

> Cadence Pharmaceuticals's stock shot up on the FDA announcement that the company does not have to conduct any additional studies of Acetavance, an intravenous version of acetaminophen. Report

> Human Genome Sciences--and other biotechs that made claims to parts of the human genetic sequence--were dealt a blow by the U.K. The High Court, which ruled on the first case to question the patentability of discoveries made through the use of bioinformatics. Report

Emerging Drug Developer: Cytochroma

And Finally... Experts now agree that bacteria, not the flu virus, caused the most deaths during the 1918 pandemic, and suggest that governments stock up on antibiotics. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.